Loading organizations...
§ Private Profile · King of Prussia, PA, USA
Biopharmaceutical company developing long-acting protein therapeutics using fusion technology for metabolic diseases.
Key people at BioRexis Pharmaceuticals Corporation.
Founded in July 2002 by David King and Christopher Prior, BioRexis Pharmaceuticals Corporation was a King of Prussia, Pennsylvania biopharmaceutical firm developing long-acting protein therapeutics for metabolic diseases using a proprietary transferrin fusion technology platform. The organization focused on addressing the short half-life of traditional drugs, aiming to reduce the need for high and frequent dosing in patients with conditions like diabetes. Prior to its exit, the enterprise secured $38 million in venture capital funding from prominent investors including SR One, Quaker BioVentures, and Alta Partners to advance preclinical drug candidates. Under the leadership of executives like Homa Sadeghi and David Holveck, the company successfully prepared its lead product for human clinical trials. The business ultimately concluded its independent operations when the pharmaceutical giant Pfizer acquired the company and its exclusive technology platform in March 2007.
Key people at BioRexis Pharmaceuticals Corporation.
BioRexis Pharmaceuticals Corporation was a biotechnology company focused on developing novel biopharmaceuticals, specializing in recombinant proteins, peptides, and proprietary Trans-bodies—engineered therapeutic agents using human transferrin technology for extended duration of action.[1][2][3] Based in King of Prussia, Pennsylvania, it targeted unmet needs in drug delivery by creating protein and peptide drugs with improved pharmacology to replace traditional antibodies.[4][5] The company served the healthcare and biotechnology sectors, solving challenges like short half-lives in protein therapeutics to enable longer-lasting treatments, though specific growth metrics or current momentum are unavailable as it appears defunct.[4]
Limited public details exist on BioRexis's founders or exact founding year, but it emerged as a biopharmaceutical innovator in the King of Prussia area, leveraging proprietary protein engineering based on human transferrin.[3][4] The idea stemmed from advancing Trans-body technology, which modifies proteins for novel therapeutics, positioning early efforts around recombinant proteins and peptides with enhanced properties.[1][2][5] Pivotal moments likely included SBIR funding pursuits and tech development in the biopharma space, though no specific traction milestones like partnerships or trials are detailed in available records.[5]
BioRexis rode the early 2000s wave of protein engineering and biologics innovation, capitalizing on trends in recombinant therapies and half-life extension technologies amid rising demand for efficient biopharmaceuticals.[3] Timing aligned with biotech's shift toward fusion proteins like transferrin-based constructs, fueled by market forces such as patent cliffs on blockbusters and needs for sustained-release drugs.[1][5] It contributed to the ecosystem by pioneering Trans-bodies, influencing subsequent advances in long-acting biologics, though its impact was niche given its Pennsylvania base and apparent closure.[4]
As a past player, BioRexis's legacy lies in its transferrin-fusion innovations, but no active operations suggest it was acquired, merged, or shuttered—common in biotech amid high failure rates.[4] Future trends like next-gen biologics (e.g., bispecifics, ADCs) build on its half-life tech, potentially amplifying its indirect influence through IP licensing or talent dispersal. Watch for echoes in modern long-acting therapies, tying back to its core mission of redefining protein drug durability.[3][5]
